B. Seifert
22.09.2009
Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07)
von Moos R, Goldinger S, Michielin O, Schuller J, Gillessen Sommer S, Schlaeppi M, Cathomas R, Ochsenbein A, Seifert B, Dummer R (2009). Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07). Präsentiert bei: ECCO / ESMO, Berlin
22.09.2009Temozolomide combined with bevacizumab in metastatic melanoma. A multicenter phase II trial (SAKK 50/07)
22.09.2009ECCO / ESMO
von Moos Roger, Goldinger S., Michielin O., Schuller J.C., Gillessen Sommer Silke, Schlaeppi Marc, Cathomas R., Ochsenbein A., Seifert B., Dummer R.
Weiter
02.12.1994
Mutant p53 protein associated with chemosensitivity in breast cancer specimens (letter)
Hornung R, Koechli O, Schaer G, Seifert B, Haller U, Eppenberger U, Mueller H. Mutant p53 protein associated with chemosensitivity in breast cancer specimens (letter). Lacet 1994; 344:1647-1648.
02.12.1994Mutant p53 protein associated with chemosensitivity in breast cancer specimens (letter)
02.12.1994Lacet 1994; 344:1647-1648
Hornung René, Koechli O., Schaer G.N., Seifert B., Haller U., Eppenberger U., Mueller H.
Weiter